Clinical Trials | September 17, 2025
Enveric clears FDA feedback milestone, prepares IND submission for EB-003
IND application for EB-003 expected in early 2026
IND application for EB-003 expected in early 2026
There is a significant unmet medical need for antidepressants that are effective, rapid onset of action and to be well tolerated
J B Chemicals and Pharmaceuticals receives ANDA approval for Amitriptyline Hydrochloride Tablets from USFDA
The product is being recalled because the infusion bag is incorrectly labeled as Levetiracetam in 0.82% Sodium Chloride Injection 500 mg/100 mL single-dose bag, while the aluminum overwrap packaging correctly identifies the product as Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 m
Dr. Prabhavathi brings over 14 years of unparalleled experience in pediatrics and a specialized focus on neurodevelopmental disorders
Olanzapine is indicated for the acute and maintenance treatment of schizophrenia and related psychotic disorders
According to IQVIA, the European market for Buprenorphine-based opioid dependency treatments in 2023 surpassed USD 355 million annually
The company will also share results in two additional posters for deuruxolitinib
The primary objective was to evaluate safety and tolerability of Ropanicant in patients with MDD
Fischer MVL envisages to offer a diverse portfolio of diagnostic solutions
Subscribe To Our Newsletter & Stay Updated
